(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa - 2Mexican Woman Accused of Assaulting Partner With Belt After He Refused Sex, Police Say
- 3Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- 4My Enterprising Excursion: Building a Startup
- 5Foreign journalist kidnapped in Iraq: Interior Ministry
- ‘Raising 10 red flags’: Is Israel’s army exhausted?
- More charges filed against ex-left-wing RAF member Daniela Klette
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- The Most Notable Design Brands of the 21st Hundred years
- 6 Web-based Course Stages for Successful Learning and Educating
- Vote In favor of Your Favored Kind Of Vegetable
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
